Kite's lead candidate axicabtagene ciloleucel ... the acquisition will take time to show its value. Gilead expects the deal to be neutral to earnings by year three and accretive thereafter ...
Vast swathes of our favourite records have somehow been passed over, unfairly dismissed or left to languish unjustly in the critical mid-table, from the little-heard cult gems to the guilty pleasures.